Adult Schizophrenia drug wins FDA approval

Teva Pharmaceuticals and MedinCell received approval from the U.S. Food and Drug Administration (FDA) for UZEDY™ (risperidone), an extended-release subcutaneous injectable for the treatment of schizophrenia in adults first approved in 1993. Uzedy™ is based in part on technology developed by researchers at Penn.Learn more on the Pharmaceutical Technology website here and in Fierce Pharma here

Skip to content